-+ 0.00%
-+ 0.00%
-+ 0.00%

Pacira transitions PCRX-201 gene therapy to scalable commercial manufacturing process in Phase 2 ASCEND study

PUBT·07/27/2026 12:04:51
Listen to the news
Pacira transitions PCRX-201 gene therapy to scalable commercial manufacturing process in Phase 2 ASCEND study
  • Pacira Biosciences shifted PCRX-201, a knee osteoarthritis gene therapy candidate, to a scalable U.S. commercial manufacturing process.
  • The new supply enabled first patient enrollment in Part B of the Phase 2 ASCEND study.
  • Topline results from Part A remain scheduled for end-2026, following completion of Part A enrollment in June.
  • Manufacturing transition supports planned registrational development, with no delay to the ongoing Phase 2 program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270800PRIMZONEFULLFEED9768049) on July 27, 2026, and is solely responsible for the information contained therein.